To: Medical Groups, DHB Hospital Pharmacies and Interested Parties

Transcription

1 24 September 2008 To: Medical Groups, DHB Hospital Pharmacies and Interested Parties CONSULTATION ON TENDER OF CERTAIN PHARMACEUTICALS ALL RESPONSES DUE BY 5PM, WEDNESDAY 5 NOVEMBER 2008 In accordance with PHARMAC s objective of securing for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided, PHARMAC is consulting on the possibility of tendering for Sole Subsidised Supply and/or Hospital Supply Status of certain pharmaceuticals listed in Schedule One of this document. Attached to this letter is a list of pharmaceuticals that we are considering tendering for Sole Subsidised Supply to community pharmacies and/or Hospital Supply Status for supply to DHB Hospital pharmacies. Pharmaceuticals are listed alphabetically by chemical, form and strength in therapeutic groups and have a C and/or H next to them to indicate whether they are being tendered for community and/or hospital supply. In general, the proposed Tender process would be similar to the 2007/08 Tender. A copy of the 2007/08 Invitation to Tender is available either on our website: or by contacting PHARMAC. Comments Sought We seek comments on the approach outlined in the following pages, in particular the following: the proposed process and timetable; the actual or potential clinical implications of awarding Sole Subsidised Supply and/or Hospital Supply Status to the pharmaceuticals listed in Schedule One; and for hospital pharmaceuticals what the appropriate Discretionary Variance Limit for each pharmaceutical would be, where a 1% Discretionary Variance Limit is considered clinically unacceptable. All comments, whether on the above described matters or not, received by 5 November 2008 will be considered by PHARMAC prior to finalisation of the 2008/09 Tender process and the list of pharmaceuticals to be tendered for Sole Subsidised Supply and/or Hospital Supply Status. A qa

2 Background Since 1997 PHARMAC has been using the strategy of tendering for sole supply of pharmaceuticals for a fixed period of time. Tendering has proven to be an effective way to encourage competition among suppliers of off patent pharmaceuticals. It is proposed that the community Tender and hospital Tender processes continue to be run in unison, however the pharmaceutical list for community and hospital pharmacies may be different. Key Aspects of Awarding a Tender for Community Pharmaceuticals: For the community pharmaceuticals the Tender winning brand would be the only subsidised brand for approximately 2½ years. The Sole Subsidised Supply period would conclude on 30 June 2012 for all awarded Tenders. The Sole Subsidised Supply brand would be fully subsidised for the Tender period which means a pharmaceutical that currently carries a manufacturer s surcharge (that is the additional patient charge above that of the patient copayment), would become fully subsidised if a Tender was awarded. No other brand of the pharmaceutical could be listed (or subsidised) on the during the Tender period (subject to any Alternative Brand Access, as proposed). Other brands could continue to be marketed, sold and dispensed in New Zealand, however they would not receive a Government subsidy. Key Aspects of Awarding a Tender for the DHB Hospital Pharmaceuticals: For the DHB Hospital pharmaceuticals, the Hospital Supply Status brand would be the only brand DHB Hospitals could purchase (excluding any allowance for alternative brands under the agreed Discretionary Variance Limits) for approximately 2½ years. The Hospital Supply Status period would conclude on 30 June 2012 for all awarded Tenders. No other brand of the pharmaceutical would be listed (or purchased) on Section H of the during the Tender period except as allowed under any DV Limits. The Process The Tender process is run annually; the proposed timelines for the 2008/09 Tender are as follows: Date September/October 2008 A qa12214 Event Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender. 5 November 2008 Final date for all consultation to be received. November 2008 Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list. 2

3 November/December 2008 Late December 2008 Late February 2009 From March June 2012 Consultation and Board decisions on Alternative Commercial Proposals to tendering from pharmaceutical suppliers. Issuing of the 2008/09 Invitation to Tender. Invitation to Tender closes. Board decisions on the first Tender winners announced. End of the sole supply period for all pharmaceuticals where a Tender is awarded from the 2008/09 Tender. Terms after the End Date may apply. Reference Pricing in the Community Reference pricing is based on the classification of pharmaceuticals into Therapeutic Subgroups. A Therapeutic Subgroup is defined as a set of pharmaceuticals that produce the same or similar therapeutic effect in treating the same or similar condition(s). The draft list contains pharmaceuticals that belong in an existing Therapeutic Subgroup. In some cases, PHARMAC may be considering tendering more than one pharmaceutical in a Therapeutic Subgroup. Where this is the case it gives rise to a number of scenarios in the community market including: 1) It is possible that awarding Sole Subsidised Supply to one pharmaceutical could result in changes to the subsidies for other pharmaceuticals in the same Therapeutic Subgroup. 2) Where more than one pharmaceutical in a Therapeutic Subgroup is included on the list, PHARMAC may award Sole Subsidised Supply to each pharmaceutical (and therefore not apply reference pricing in the usual way) or may only award Sole Subsidised Supply to one pharmaceutical and apply reference pricing to the others. Such scenarios could give rise to new or increased manufacturer surcharges. We ask that you consider any clinical considerations associated with such scenarios. Contractual obligations for suppliers A copy of the draft contractual requirements which would form the terms of the contract with successful suppliers in the 2008/09 Tender is available on the PHARMAC website: or by phoning PHARMAC on Unresolved Tender Bids PHARMAC would review any unresolved Tender Bids from the Invitation to Tender dated 15 December 2006 (2006/07 Tender) and the Invitation to Tender dated 21 December 2007 (2007/08 Tender) prior to issuing the 2008/09 Tender. Should any unresolved Tender Bids be declined, PHARMAC would consider re-tendering those pharmaceuticals when the Invitation to Tender is issued in December Currently unresolved Tender Bids have not been included in the draft pharmaceutical list set out A qa

4 in Schedule One of this document. PHARMAC is currently seeking comments from suppliers about keeping any unresolved Tender Bid(s) open for acceptance. Access to Alternative Brands PHARMAC is continuing work to identify mechanisms that can reduce the impact on patients of brand changes. We will keep you informed as this work continues to progress. In the meantime, PHARMAC has undertaken a preliminary assessment to determine which products are appropriate for inclusion in this years tender. We welcome specific comments in relation to any implications of tendering items included in Schedule Two. Distribution of Consultation Documents Please note that this consultation letter has been widely distributed however should you consider that a particular person, group or agency should receive this and future Tender documents please feel free to contact PHARMAC (also available from our website). We also invite any person or group to contact PHARMAC should you wish to have a meeting to discuss this consultation document. Please direct any queries you may have to Yvonne Chen [DDI: (04) ] at PHARMAC for questions in relation to community supply, and Andrew Davies [DDI: (04) ] for questions in relation to hospital supply. Yours sincerely Steffan Crausaz Manager, Funding and Procurement A qa

5 Possible pharmaceuticals for tender for sole supply Order of pharmaceuticals in this Annex The pharmaceuticals have been listed in therapeutic groups according to the classification system used in the. Below is a list of the groups, and the corresponding page numbers for your ease of reference. Please note that pharmaceuticals with indications that may apply to multiple therapeutic groups will only appear in one. Therapeutic Group Page Numbers Alimentary Tract and Metabolism 7 8 Blood and Blood Forming Organs 8 9 Cardiovascular System 9 12 Dermatologicals Extemporaneously Compounded Preparations 13 Genito-Urinary System 13 Hormone Preparations Systemic excluding contraceptives Infections Agents for Systemic Use Musculo-Skeletal System Nervous System Oncology and Immunosuppressants Respiratory System and Allergies Sensory Organ 25 Special Foods Information provided for each pharmaceutical For each pharmaceutical (as defined by chemical name, form and strength) we have provided the following information: the current ex-manufacturer subsidy per unit of measure as at 1 September 2008; number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2008; estimated annual community market value at current subsidies; and comments specifically relating to the Tender of the line item and/or its current listing on the. The figures for the number of units subsidised in community pharmacies are approximate and are based on the year ending June These figures are indicative only and sales are not guaranteed. PHARMAC makes no representation as to the level of sales or likely sales of any tender item. There are no figures available for hospital pharmaceuticals. A qa

6 We have estimated market value by multiplying the volume of units subsidised in the year ending 30 June 2008 by the relevant listed unit subsidy as at 1 September Patents A number of pharmaceuticals included in this list may still be on patent. Based on information available to PHARMAC, we believe these patents will expire by within the sole supply period. While PHARMAC has taken care in preparing the information contained in this table, it does not make any representation as to the accuracy of this information and accepts no liability in the event that the information is incorrect. Suppliers remain responsible for ensuring they do not infringe patents. Suppliers are responsible for their own independent assessment of the information and must decide for themselves whether or not to make an investment and on what terms. Explanation of terms, symbols and abbreviations Most terms and abbreviations used are self explanatory: tab means tablet, cap means capsule, liq means liquid, inj means injection, suppos means suppository, grans mean granules and OP means original pack to be dispensed. The following table explains the symbols used in the draft pharmaceutical list: Symbol Explanation Pharmaceutical line items where a sole supply contract is in force are underlined. The price and subsidy for these pharmaceuticals are fixed until 30 Underline June 2009 unless otherwise stated in the Comments column and a listing of a new brand could only occur until after that date. C To be tendered for Sole Subsidised Supply (community pharmaceuticals). H To be tendered for Hospital Supply Status (DHB Hospital pharmaceuticals). A reference in the Invitation to Tender to allow Pharmaceuticals Cancer PCT Treatments to be listed in Section B of the as part of PHARMAC s Pharmaceutical Cancer Treatments project. + PHARMAC has been advised of the existence of a process patent. There is no fully funded product available for this line item (in relation to * community supply). A qa

7 Alimentary Tract and Metabolism Acarbose Tab 50 mg 501,151 $122,504 $ Tab 100 mg 178,370 $61,439 $ Amphotericin B Emulsion for infusion 5 mg per ml Liposomal Inj 50 mg Not currently listed in the Ascorbic Acid Inj 500 mg per 5 ml H 1% Tab 50 mg Tab 100 mg 1,163,211 $40,131 $ Tab 250 mg Atropine Sulphate Inj 400 mcg, 1 ml Not currently listed in the Inj 600 mcg, 1 ml 74,203 $38,586 $ Inj 1200 mcg, 1 ml 8,555 $5,475 $ Calcitriol Cap 0.25 mcg 2,655,022 $357,100 $ Cap 0.5 mcg 374,927 $93,544 $ Calcium Carbonate with Aminoacetic Acid Tab mg with aminoacetic acid 180 mg 1,309,386 $39,282 $ Dose range of mg elemental calcium per tablet required Calcium Gluconate Inj 10%, 10 ml 1,666 $3,565 $ Famotidine Tab 20 mg 794,073 $25,728 $ C Tab 40 mg 663,356 $30,116 $ C Glycopyrronium Inj 0.2 mg per ml, 1 ml H 1% Hydrocortisone Acetate Rectal foam 10 %, CFC-free 246,692 $246,692 $ Iodine Soln aqueous BP C. A Special Authority or endorsement (for use during pregnancy and breastfeeding only) may be applied. 7

8 Iodine Tab mcg C. A Special Authority or endorsement (for use during pregnancy and breastfeeding only) may be applied. A combination product would be considered; however it must contain 150 mcg -200 mcg of iodine. Lansoprazole Cap 15 mg 134,230 $20,618 $ Cap 30 mg 1,155,646 $354,536 $ Mesalazine Enema 1 g per 100 ml 44,152 $295,818 $ Metformin Hydrochloride Tab 500 mg 65,764,349 $1,282,405 $ Tab 850 mg 14,906,417 $477,005 $ Miconazole Oral gel 20 mg per g 627,525 $140,409 $ C Mucilaginous Laxatives Dry 52,686,510 $927,283 $ Dry-original flavour, regular texture only 7,344,541 $129,264 $ Sugar Free 1,074,077 $18,904 $ Pyridoxine Hydrochloride Tab 50 mg 1,329,155 $46,866 $ C Thiamine Hydrochloride Inj 100 mg per ml, 2 ml Vitamin B Complex Tab, strong, BPC 2,181,455 $52,791 $ C Vitamins Tab (BPC cap strength) 26,540,856 $392,805 $ C Blood and Blood Forming Organs Aprotinin Inj 10,000 mcg per ml, 100 ml Inj 10,000 mcg per ml, 200 ml Atorvastatin Tab 10 mg 4,043,571 $543,052 $ * C Tab 20 mg 5,720,682 $1,119,537 $ * + C Tab 40 mg 7,361,373 $1,997,140 $ * + C + 8

9 Atorvastatin Tab 80 mg + C Filgrastim Inj 0.3 mg per ml, 1 ml H 1% Folic Acid Tab 0.8 mg 2,762,493 $45,581 $ C Tab 5 mg 5,910,478 $77,900 $ C Gemfibrozil Cap 300 mg Hydroxocobalamin Inj 1 mg per ml, 1 ml 229,445 $704,396 $ Currently two different subsidies, unit subsidy reflects the lower of the two Magnesium Sulphate Inj 49.3%, 5 ml H 1% Nicotinic Acid Tab 25 mg C Tab 50 mg 1,158,927 $58,873 $ C Tab 100 mg C Tab 500 mg 725,913 $127,761 $ C Phenindione Tab 10 mg H 1% Tab 25 mg H 1% Tab 50 mg H 1% Potassium Chloride Tab long-acting 600 mg 11,543,083 $300,120 $ Sodium Bicarbonate Inj 8.4%, 50 ml 1,927 $38,444 $ Inj 8.4% 100 ml 2,203 $45,162 $ Inf 5%, 500 ml H 1% Tranexamic Acid Inj 100 mg per ml, 5 ml H 1% Urokinase Inj 10,000 iu H 1% Inj 500,000 iu H 1% Cardiovascular System 9

10 Aprotinin Inj 10,000,000 iu per ml, 50 ml * Arginine Inj 5%, 500 ml H 1% Atenolol Tab 50 mg 9,451,084 $122,864 $ Tab 100 mg 3,407,916 $77,019 $ Celiprolol Tab 200 mg 6,179,652 $652,571 $ Clonidine Inj 150 mcg per ml, 1 ml 8,495 $23,786 $ Tab 25 mcg 2,622,929 $459,799 $ Tab 150 mcg 507,228 $153,842 $ TDDS 2.5 mg, 100 mcg per day 36,752 $195,613 $ TDDS 5 mg, 200 mcg per day 12,937 $99,583 $ TDDS 7.5 mg, 300 mcg per day 9,885 $96,626 $ Dobutamine Inj 12.5 mg per ml, 20 ml H 1% Enalapril Tab 2.5 mg Tab 5 mg 4,518,231 $109,944 $ Tab 10 mg 3,869,420 $118,662 $ Tab 20 mg 3,152,044 $128,884 $ Enalapril With Hydrochlorothiazide Tab 20 mg with hydrochlorothiazide 12.5 mg 426,921 $47,246 $ * Felodipine Tab long-acting 2.5 mg 8,177,612 $2,829,454 $ Tab long-acting 5 mg 14,589,483 $2,674,739 $ Tab long-acting 10 mg 10,114,257 $2,697,135 $ Flecainide Acetate Cap long-acting 100 mg 648,558 $925,687 $ Cap long-acting 200 mg 522,648 $1,317,596 $ Inj 10 mg per ml, 15 ml 18 $176 $ Tab 50 mg 249,598 $178,138 $ Tab 100 mg 239,890 $302,381 $ Frusemide Tab 40 mg 36,001,746 $414,020 $

11 Frusemide Tab 500 mg 220,562 $26,467 $ Glyceryl Trinitrate Inj 1 mg per ml, 5 ml H 1% Inj 1 mg per ml, 50 ml H 1% Inj 5 mg per ml, 1 ml H 1% Inj 5 mg per ml, 10 ml H 1% Hydralazine Inj 20 mg per ml, 1 ml 463 $2,398 $ Hydrochlorothiazide Tab 12.5 mg Tab 25 mg Lisinopril Tab 2.5 mg C C Tab 5 mg 606,533 $56,205 $ Tab 10 mg 575,487 $60,618 $ Tab 20 mg 717,210 $93,476 $ Lisinopril with Hydrochlorothiazide Tab 20 mg with hydrochlorothiazane 12.5 mg Losartan Tab 12.5 mg 1,423,394 $825,569 $ Tab 25 mg 105 $76 $ This was recently listed on the Pharmaceutical Schedule Tab 50 mg 2,186,442 $1,683,560 $ Tab 100 mg 165,131 $194,855 $ Tab 50 mg with hydrochlorothiazide 12.5 mg 569,215 $569,215 $ Tab 100 mg with hydrochlorothiazide 25 mg Not currently listed in the Metaraminol Tartrate Inj 10 mg per ml, 1 ml H 1% Milrinone Inj 1 mg per ml, 10 ml H 1% Noradrenaline Acid Tartrate Inj 0.1 mg per ml, 100 ml bag H 1% Phenoxybenzamine Inj 100 mg per 2 ml H 1% 11

12 Pindolol Tab 5 mg 311,631 $14,023 $ Tab 10 mg 318,076 $26,559 $ Tab 15 mg 155,255 $18,631 $ Propranolol Cap long-acting 160 mg 657,431 $111,106 $ Tab 10 mg 1,986,827 $70,532 $ Tab 40 mg 2,286,674 $106,330 $ Timolol maleate Tab 10 mg 193,209 $20,384 $ C Acitretin Dermatologicals Cap 10 mg 286,675 $271,625 $ C Cap 25 mg 87,123 $177,470 $ C Betamethasone Valerate Scalp app 0.1% 3,105,621 $163,045 $ Calamine Crm, aqueous, BP 176,113 $5,319 $ C Lotn, BP 4,284,946 $41,650 $ C Chlorhexidine Crm 1% obstetric H 1% Chlorhexidine Gluconate Handrub 0.5% - 1% with ethanol 70% 2,168,302 $23,418 $ C Chlorhexidine strengths from 0.5% to 1% would be considered Ciclopiroxolamine Crm 1% 36,090 $1,805 $ * C Nail soln 8% 58,828 $635,510 $ * C Soln 1% 35,599 $7,761 $ * C Clobetasol Propionate Crm 0.05% 2,450,584 $191,962 $ Oint 0.05% 2,357,714 $125,745 $ Scalp app 0.05% 595,476 $63,517 $ Hydrocortisone Crm 1% (pack size 15 g or less) 17,399,193 $424,540 $ Volume is aggregated for all pack sizes of hydrocortisone cream Crm 1% (pack size greater than 15 g and 100 g or less) 17,399,193 $424,540 $ Volume is aggregated for all pack sizes of hydrocortisone cream 12

13 Hydrocortisone with Miconazole Crm 1% with miconazole nitrate 2% 3,308,557 $485,365 $ C Isotretinoin Cap 10 mg 1,079,577 $388,648 $ Information on appropriate use should be available on a website Cap 20 mg 1,942,915 $922,885 $ Information on appropriate use should be available on a website. Cap 40 mg Information on appropriate use should be available on a website. Not currently listed on the Pharmaceutical Schedule. Mupirocin Nasal oint 2% H 1% Paraffin White soft or yellow soft (pack size 30 g or less) H 1% Extemporaneously Compounded Preparations and Galenicals Sodium Bicarbonate Powder BP 168,898 $3,310 $ Genito-Urinary System Alprostadil Inj 0.5 mg per ml, 1 ml H 1% Ergometrine Maleate Inj 500 mcg per ml, 1 ml 2,106 $4,886 $ Norethisterone Tab 350 mcg 9,474,169 $806,432 $ C Oxytocin Inj 5 iu per ml, 1 ml 965 $1,042 $ Inj 10 iu per ml, 1 ml 4,462 $6,068 $ Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml 2,783 $5,121 $ Pregnancy Tests - HCG Urine Urine diagnostic test 361,483 $274,727 $ Hormone Preparations - Systemic Excluding Contraceptive Hormones Clomiphene Citrate Tab 50 mg 44,271 $22,136 $ C Cyproterone Acetate Tab 50 mg 996,277 $468,250 $ Tab 100 mg 13

14 Danazol Cap 100 mg 12,211 $10,175 $ Cap 200 mg 30,018 $17,011 $ Dexamethasone Sodium Phosphate Inj 4 mg per ml, 1 ml 19,530 $83,979 $ Inj 4 mg per ml, 2 ml 72,426 $449,041 $ Ethinyloestradiol Tab 10 mcg 305,869 $53,833 $ C Etidronate Disodium Tab 200 mg 1,719,628 $653,459 $ Hydrocortisone Tab 5 mg 2,440,393 $194,011 $ Tab 20 mg 141,826 $28,294 $ Methylprednisolone Inj 500 mg 308 $5,067 $ Inj 1 g 290 $12,345 $ Tab 4 mg 26,618 $12,928 $ Tab 100 mg 17,765 $147,911 $ Methylprednisolone Sodium Succinate Inj 40 mg per ml, 1 ml 1,204 $7,291 $ Inj 62.5 mg per ml, 2 ml 834 $13,764 $ Oestrogens Conjugated, equine tab 300 mcg 1,203,803 $129,409 $ * C Testosterone Transdermal patch 2.5 mg per day 104,975 $139,963 $ Infections - Agents for Systemic Use Abacavir Sulphate Oral liq 20 mg per ml 26,298 $10,958 $ Tab 300 mg 72,537 $553,699 $ Abacavir sulphate with lamivudine Tab 600 mg with lamivudine 300 mg 36,458 $765,618 $ Aciclovir Inj 250 mg H 1% Inj 500 mg H 1% Inj 1,000 mg H 1% + 14

15 Aciclovir Tab 200 mg Tab 400 mg Tab 800 mg Dispersible tablets need to remain subsidised for patients who are unable to swallow tablets and the prescription is endorsed accordingly. Not currently listed on the Pharmaceutical Schedule. Dispersible tablets need to remain subsidised for patients who are unable to swallow tablets and the prescription is endorsed accordingly. Not currently listed on the Pharmaceutical Schedule. Dispersible tablets need to remain subsidised for patients who are unable to swallow tablets and the prescription is endorsed accordingly. Not currently listed on the Pharmaceutical Schedule. Tab dispersible 200 mg 815,115 $64,557 $ Tab dispersible 400 mg 3,046,791 $361,349 $ Tab dispersible 800 mg 497,147 $104,848 $ Amikacin Inj 5 mg per ml, 5 ml H 1% Inj 250 mg per ml, 2 ml H 1% Amoxycillin Grans for oral liq 125 mg per 5 ml 29,891,936 $298,919 $ Grans for oral liq 250 mg per 5 ml 22,765,928 $289,127 $ Sachets 3 g Amoxycillin Clavulanate Grans for oral liq amoxycillin 125 mg with potassium clavulanate mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml 12,012,266 $330,337 $ ,612,478 $741,593 $ Azithromycin Tab 500 mg 93,956 $465,082 $ Caspofungin Inj 50 mg H 1% Inj 70 mg H 1% Cefazolin Sodium Liq Cephradine Liq 15

16 Chloroquine Oral liq Tab 200 mg mg Dicloxacillin Inj 500 mg C C Erythromycin Ethyl Succinate Tab 400 mg 4,664,291 $883,883 $ Flucloxacillin Sodium Cap 250 mg 1,289,694 $95,437 $ Cap 500 mg 7,610,215 $881,263 $ Grans for oral liq 125 mg per 5 ml 4,295,279 $88,053 $ Grans for oral liq 250 mg per 5 ml 5,616,300 $152,763 $ Fluconazole Inj 2 mg per ml, 50 ml H 1% Gentamicin Sulphate Inj 40 mg per ml, 2 ml 6,288 $2,867 $ Lamivudine Oral liq 5 mg per ml 240 $90 $ C Oral liq 10 mg per ml 83,825 $34,930 $ C Tab 100 mg 299,522 $1,529,689 $ C Tab 150 mg 80,464 $411,976 $ C Nevirapine Oral suspension 10 mg per ml 43,764 $24,534 $ Oral suspension 50 mg per 5 ml Tab 200 mg 123,184 $656,571 $ Pyrantel Embonate Oral suspension Tab $ * A variety of oral solid dose forms would be considered. Note this product has been discontinued. Roxithromycin Tab 150 mg 1,711,147 $325,118 $ Tab 300 mg 700,273 $252,098 $ Streptomycin Inj 1 g H 1% 16

17 Tetracycline Hydrochloride Cap 250 mg Ticarcillin Inj 1 g Inj 3 g H 1% H 1% Zidovudine (AZT) with Lamivudine Tab 300 mg with lamivudine 150 mg 363,685 $4,044,177 $ C Musculo-Skeletal System Baclofen Inj 10 mg Oral liq 5 mg per 5 ml Pharmaceuticcal Schedule Tab 10 mg Tab 20 mg Dantrolene Sodium Cap 25 mg 130,888 $43,141 $ Cap 50 mg 53,732 $27,779 $ Inj 1 mg per ml, 20 ml H 1% Diclofenac Sodium Cap long-acting 100 mg Tab 50 mg dispersible 813,172 $60,988 $ Tab EC 25 mg 498,946 $17,513 $ Tab EC 50 mg 3,827,691 $198,121 $ Tab long-acting 75 mg 21,240,802 $967,731 $ Tab long-acting 100 mg 4,444,439 $305,066 $ Leflunomide Tab 10 mg 163,670 $432,471 $ Tab 20 mg 388,518 $1,406,435 $ Tab 100 mg 25 $454 $ Naproxen Tab 250 mg 1,138,443 $47,815 $ Tab 500 mg 2,585,347 $185,628 $ Quinine Sulphate Tab 200 mg 1,894,387 $120,862 $ Tab 300 mg 3,544,411 $246,337 $

18 Raloxifene Tab 60 mg. Tender Agreement may be subject to an endorsement or Special Authority restriction Rasburicase Inj 1.5 mg H 1% Nervous System Apomorphine Hydrochloride Inj 10 mg per ml, 1 ml 8,036 $81,051 $ Atracurium Besylate Inj 10 mg per ml, 2.5 ml H 1% Inj 10 mg per ml, 5 ml H 1% Bupivacaine hydrochloride Inf 0.125%, 100 ml H 1% Inf 0.125%, 200 ml H 1% Inf 0.25%, 100 ml H 1% Inj 0.25%, 20 ml H 1% Inj 0.375%, 20 ml H 1% Inj 0.5%, 4 ml theatre pack H 1% Inj 0.5%, 10 ml H 1% Inj 0.5%, 10 ml Theatre pack H 1% Inj 0.5%, 20 ml H 1% Inj 0.5%, 20 ml Theatre pack H 1% Bupivacaine Hydrochloride with Adrenaline Inj 0.25% with 1:400,000 of adrenaline, 10 ml H 1% Inj 0.25% with 1:400,000 of adrenaline, 10 ml theatre pack H 1% Inj 0.25% with 1:400,000 of adrenaline, 20 ml H 1% Inj 0.25% with 1:400,000 of adrenaline, 20 ml theatre pack H 1% Inj 0.5% with 1:200,000 of adrenaline, 10 ml H 1% Inj 0.5% with 1:200,000 of adrenaline, 10 ml theatre pack H 1% Inj 0.5% with 1:200,000 of adrenaline, 20 ml H 1% Inj 0.5% with 1:200,000 of adrenaline, 20 ml theatre pack H 1% Cocaine Soln 4%, 2 ml BP H 1% 18

19 Cyclizine Hydrochloride Tab 50 mg 677,078 $134,739 $ Cyclizine Lactate Inj 50 mg per ml, 1 ml 56,899 $170,128 $ Diazepam Rectal tubes 5 mg 11,015 $61,309 $ Rectal tubes 10 mg 15,928 $246,151 $ Dopamine Inj 40 mg per ml, 5 ml H 1% Entacapone Tab 200 mg 391,751 $505,359 $ Ephedrine Sulphate Inj 30 mg per ml, 1 ml H PCT 1% Ergotamine Tartrate with Caffeine Tab 1 mg with caffeine 100 mg 462,764 $143,457 $ Fentanyl Inj 50 mcg per ml, 2 ml Inj 50 mcg per ml, 5 ml Inj 50 mcg per ml, 10 ml Inj 50 mcg per ml, 20 ml Gabapentin Cap 100 mg 895,270 $118,713 $ C H 5% Tender Agreement may be subject to an endorsement or Special Authority restriction. Currently two different subsidies. Unit Subsidy reflects the lower of the two. Cap 300 mg 6,568,959 $2,613,789 $ C H 5% Tender Agreement may be subject to an endorsement or Special Authority restriction. Currently two different subsidies. Unit Subsidy reflects the lower of the two. Cap 400 mg 814,273 $431,646 $ C H 5% Tender Agreement may be subject to an endorsement or Special Authority restriction. Currently two different subsidies. Unit Subsidy reflects the lower of the two. Tab 600 mg 43,134 $34,417 $ C H 5% Tender Agreement may be subject to an endorsement or Special Authority restriction. Currently two different subsidies. Unit Subsidy reflects the lower of the two. 19

20 Imipramine Hydrochloride Tab 10 mg 480,347 $84,541 $ Tab 25 mg 1,637,443 $179,464 $ Ketamine Inj 100 mg per ml, 2 ml H 1% Levodopa with Benserazide Cap 50 mg with benserazide 12.5 mg 1,017,949 $81,436 $ Cap 100 mg with benserazide 25 mg 1,218,285 $152,286 $ Cap long-acting 100 mg with benserazide 25 mg 654,911 $111,335 $ Cap 200 mg with benserazide 50 mg 153,844 $38,461 $ Tab dispersible 50 mg with benserazide 12.5 mg 580,338 $58,034 $ Lignocaine Gel 2% H 1% Lorazepam Tab 1 mg 4,401,220 $110,559 $ Tab 2.5 mg 256,674 $10,575 $ Maprotiline Hydrochloride Tab 25 mg 92,569 $23,198 $ Tab 75 mg 16,952 $11,871 $ Methadone Hydrochloride Oral liq 2 mg per ml 2,398,374 $78,547 $ Oral liq 5 mg per ml 20,903,093 $681,441 $ Oral liq 10 mg per ml 2,995,585 $142,290 $ Methylphenidate Hydrochloride Tab immediate-release 5 mg 102,380 $10,924 $ Tab immediate-release 20 mg 34,071 $8,916 $ Tab immediate-release 10 mg 2,350,074 $336,061 $ Tab sustained-release 20 mg 2,445,000 $892,425 $ Excludes long-acting or extended-release products Metoclopramide Hydrochloride with Paracetamol Tab 5 mg with paracetamol 500 mg 1,304,831 $70,670 $ C Midazolam Inj 1 mg per ml, 5 ml H 1% Inj 5 mg per ml, 3 ml H 1% Moclobemide Tab 150 mg 1,491,347 $147,494 $ Tab 300 mg 356,795 $93,159 $

21 Morphine Hydrochloride Oral liq 1 mg per ml 5,435,380 $219,046 $ Oral liq 2 mg per ml 714,066 $30,562 $ Oral liq 5 mg per ml 1,004,181 $48,251 $ Oral liq 10 mg per ml 585,791 $36,788 $ Morphine Sulphate Cap long-acting 10 mg 2,944,101 $529,938 $ Cap long-acting 30 mg 1,014,236 $267,758 $ Cap long-acting 60 mg 407,958 $293,730 $ Cap long-acting 100 mg 299,552 $235,148 $ Inj 5 mg per ml, 1 ml 22,986 $23,768 $ Inj 15 mg per ml, 1 ml 11,669 $10,969 $ Tab immediate release 10 mg 1,289,061 $340,312 $ Tab immediate release 20 mg 659,111 $336,147 $ Tab long-acting 10 mg 772,937 $139,129 $ Tab long-acting 30 mg 388,234 $139,764 $ Tab long-acting 60 mg 185,167 $133,320 $ Tab long-acting 100 mg 253,839 $215,763 $ Morphine Tartrate Inj 80 mg per ml, 1.5 ml 23,383 $94,467 $ Inj 80 mg per ml, 5 ml 1,793 $24,159 $ Oxycodone Hydrochloride Cap 5 mg 512,539 $72,524 $ Cap 10 mg 346,876 $96,778 $ Cap 20 mg 233,842 $114,232 $ Tab controlled-release 5 mg 345,357 $129,682 $ Tab controlled-release 10 mg 709,346 $395,106 $ Tab controlled-release 20 mg 524,147 $496,105 $ Tab controlled-release 40 mg 173,489 $288,772 $ Tab controlled-release 80 mg 112,353 $325,992 $ Pancuronium bromide Inj 2 mg per ml, 2 ml H 1% Paracetamol Suppos 125 mg 69,308 $22,560 $ Suppos 250 mg 62,963 $39,415 $ Tab modified-release 665 mg C 21

22 Pethidine Hydrochloride Inj 50 mg per ml, 1 ml 33,594 $25,196 $ Inj 50 mg per ml, 1.5 ml 201 $175 $ Inj 50 mg per ml, 2 ml 71,687 $59,930 $ Rocuronium Inj 10 mg per ml, 5 ml H 1% Inj 10 mg per ml, 10 ml H 1% Selegiline Hydrochloride Tab 5 mg 179,760 $28,869 $ C Tetrabenazine Tab 25 mg 111,640 $242,219 $ C Tropisetron Cap 5 mg 8,623 $133,501 $ Inj 1 mg per ml, 2 ml Vecuronium Inj 4 mg H 1% Inj 10 mg H 1% Zuclopenthixol Hydrochloride Tab 2 mg Tab 10 mg Tab 25 mg Tab 40 mg Oncology Agents and Immunosuppressants Amsacrine Inj 50 mg per 1 ml H 1% Bleomycin sulphate Inj 15,000 iu H PCT 1% Capecitabine Tab 150 mg 613,071 $3,601,792 $ Tab 500 mg 117,595 $225,394 $ Carboplatin Inj 10 mg per ml, 5 ml H PCT 1% Inj 10 mg per ml, 10 ml H PCT 1% Inj 10 mg per ml, 15 ml H PCT 1% Inj 10 mg per ml, 45 ml H PCT 1% 22

23 Carboplatin Inj 10 mg per ml, 100 ml H PCT 1% Carmustine Inj 100 mg, 3 ml H PCT 1% Cyclosporin Inf 50 mg per ml, 5 ml H 1% Dacarbazine Inj 200 mg H PCT 1% Daclizumab Inj 25 mg per 5 ml H 1% Doxorubicin Inj 10 mg H PCT 1% Inj 20 mg H PCT 1% Inj 50 mg H PCT 1% Inj 100 mg H PCT 1% Inj 200 mg H PCT 1% Epirubicin Inj 1 mg per ml, 5 ml H PCT 1% Inj 2 mg per ml, 2 ml H PCT 1% Inj 2 mg per ml, 5 ml H PCT 1% Inj 2 mg per ml, 10 ml H PCT 1% Inj 2 mg per ml, 25 ml H PCT 1% Inj 2 mg per ml, 50 ml H PCT 1% Inj 2 mg per ml, 100 ml H PCT 1% Etoposide Cap 50 mg 6,196 $105,558 $ C H PCT 1% Cap 100 mg 1,059 $36,083 $ C H PCT 1% Inj 20 mg per ml, 20 ml H PCT 1% Inj 20 mg per ml, 50 ml H PCT 1% Idarubicin hydrochloride Cap 5 mg H PCT 1% Cap 10 mg H PCT 1% Inj 5 mg H PCT 1% Inj 10 mg H PCT 1% Irinotecan Inj 20 mg per ml, 2 ml H PCT 1% Inj 20 mg per ml, 5 ml H PCT 1% 23

24 Letrozole Tab 2.5 mg 403,568 $1,970,219 $ Methotrexate Tab 2.5 mg 1,816,012 $351,096 $ C H PCT 1% Tab 10 mg 254,883 $208,647 $ C H PCT 1% Mycophenolate Mofetil Cap 250 mg 255,891 $528,824 $ Inj 500 mg H 1% Powder for oral liq 1 g per 5 ml 9,177 $15,851 $ Tab 500 mg 446,759 $1,846,544 $ Oxaliplatin Inj 50 mg H PCT 1% Inj 100 mg H PCT 1% Vincristine Sulphate Inj 1 mg per ml, 1 ml H PCT 1% Inj 1 mg per ml, 2 ml H PCT 1% Vinorelbine Inj 10 mg per ml, 1 ml H PCT 1% Inj 10 mg per ml, 5 ml H PCT 1% Beclomethasone Dipropionate Respiratory System and Allergies Metered aqueous nasal spray, 50 mcg per dose 11,712,396 $137,621 $ Metered aqueous nasal spray, 100 mcg per dose 44,054,856 $541,875 $ Beractant Inj 25 mg per ml, 8 ml H 1% Budesonide Metered aqueous nasal spray, 50 mcg per dose 5,253,314 $61,726 $ * Metered aqueous nasal spray, 100 mcg per dose 29,732,447 $388,008 $ * Nebuliser soln, 500 mcg per ml, 2 ml H 1% Nebuliser soln, 1 mg per ml, 2 ml H 1% Chlorpheniramine Maleate Cap long-acting 12 mg Not currently subsidised on the Pharmaceutical Schedule Salbutamol Nebuliser soln, 1 mg per ml, 2.5 ml 441,581 $81,692 $ Nebuliser soln, 2 mg per ml, 2.5 ml 1,052,618 $202,629 $

25 Salbutamol with Ipratropium Bromide Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml 1,256,489 $332,970 $ Sodium Cromoglycate Nasal spray, 4% 49,813 $30,567 $ C Acetylcholine Sensory Organs Inj 10 mg per ml, 2 ml H 1% Betaxolol Hydrochloride Eye drops 0.25% 65,418 $154,386 $ C Eye drops 0.5% 9,179 $13,769 $ C Bimatoprost Eye Drops 0.03% 115,766 $752,479 $ C Chloramphenicol Eye drops 0.5% 1,671,053 $233,947 $ Single dose presentation would not be a DV Pharmaceutical Eye oint 1% 451,236 $279,766 $ Dorzolamide Hydrochloride Eye drops 2% 27,856 $54,431 $ * C Dorzolamide hydrochloride with timolol maleate Eye drops 2% with timolol maleate 0.5% 323,288 $1,196,166 $ Fluorometholone Eye drops 0.1% 64,020 $55,057 $ Sodium Cromoglycate Eye drops 2% 442,865 $174,932 $ C Sodium Hyaluronate Inj 3% with 4% chondroitin sulphate, 0.35 ml H 1% Inj 3% with 4% chondroitin sulphate, 0.5 ml H 1% Ophthalmic inj 14 mg per ml H 1% Ophthalmic soln 10 mg per ml H 1% Sodium Hyaluronidate Inj 14 mg per ml H 1% Travoprost Eye drops 0.004% 94,418 $736,460 $ C Triamcinolone acetonide with gramicidin, neomycin and nystatin Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g 176,287 $78,742 $ Special Foods + 25

26 Oral Feed 1.5 KCal per ml Liq 774,764,134 $4,338,679 $ * Sole supply could be awarded for a range of flavours from only one supplier. This line item describes oral feed listed under the "Adult Products Standard" therapeutic subgroup in the. Liq with fibre 73,903,400 $413,859 $ Sole supply could be awarded for a range of flavours from only one supplier. This line item describes oral feed listed under the "Adult Products Standard" therapeutic subgroup in the. 26